首页> 外文OA文献 >481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy

【2h】

481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy

机译：481tip Checkmate 722：在EGFR酪氨酸激酶抑制剂（Tki ）治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
K. Nakagawa; J.C.-H. Yang; K. Park; Y. Ohe; Y.-L. Wu; J. Gainor; A. Blackwood-Chirchir; R. Yang; I.-F. Chang; T. Mok;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 第一代EGFR酪氨酸激酶抑制剂治疗106例复合EGFR突变肺癌患者:一项单中心临床研究 [J] . Xiangyang Yu, Xuewen Zhang, Zichen Zhang, 癌症（英文版） . 2019,第010期
2. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation [J] . Yan Xiangtao, Wang Huijuan, Li Peng, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2019,第期

机译：单独或与低丰度突变的先进非小细胞肺癌（NSCLC）组合单独使用表皮生长因子受体 - 酪氨酸激酶抑制剂（EGFR-TKI）的疗效。
3. An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-na?ve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227) [J] . Matthew Hellmann, Suresh Ramalingam, Martin Reck, Journal for ImmunoTherapy of Cancer . 2015,第S2期

机译：一项针对nivolumab初治IV期或复发性非小细胞肺癌（NSCLC）患者的nivolumab或nivolumab联合ipilimumab与铂类双重化疗（PT-DC）的开放标签随机III期试验（CheckMate 227）
4. The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials [J] . Hasegawa Yoshikazu, Ando Masahiko, Maemondo Makoto, The oncologist . 2015,第3期

机译：吸烟状态在非活化小细胞肺癌患者无进展生存中的作用，该患者具有接受一线EGFR酪氨酸激酶抑制剂与铂类双重治疗的活化表皮生长因子受体（EGFR）突变：前瞻性随机试验的荟萃分析。
5. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
6. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
7. An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227) [O] . Matthew Hellmann, Suresh Ramalingam, Martin Reck, 2015

机译：一项针对nvolumab或nivolumab联合ipilimumab与铂类双重化疗（PT-DC）的初治IV期或复发性非小细胞肺癌（NSCLC）患者的开放标签随机III期临床试验（CheckMate 227）
8. An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227) [O] . Matthew Hellmann, Suresh Ramalingam, Martin Reck, 2015

机译：一项针对nvolumab或nivolumab联合ipilimumab与铂类双重化疗（PT-DC）的初治IV期或复发性非小细胞肺癌（NSCLC）患者的开放标签随机III期临床试验（CheckMate 227）

481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy

著录项

引文网络

相似文献

相关主题

期刊订阅